Allogeneic Hematopoietic Stem Cell Transplantation as a Platform to Treat Chemorefractory Acute Myeloid Leukemia in Adult Patients.

Cancers (Basel) · 2025 · PMC12564749 · PMID 41154342

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Three-year OS was 34%, 29%, and 41% in the three groups, respectively, with a nonsignificant trend towards better OS for patients with relapsed AML and a peak 3-year OS of 51% in patients transplanted with leukemic BM infiltration <20%.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.